Title: 
Official Title: To amend title 35, United States Code, to prevent double patenting, and for other purposes.
Number of Sections: 2
Source: versions - Introduced in House
Media Type: text/xml

================================================================================

Section 1:
1.Short titleThis Act may be cited as the Stopping Pharma’s Ripoffs and Drug Savings For All Act.

Section 2:
2.Prevention of double patenting (a)In generalSection 253 of title 35, United States Code, is amended by adding at the end the following:

(c)Disclaimers of drug patent term
(1)In generalExcept as provided in paragraph (2), in a proceeding challenging the validity of patents under section 505(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)) with respect to a drug, under section 351(l) of the Public Health Service Act (42 U.S.C. 262(l)) with respect to a biological product, or a Federal district court proceeding involving patents that are the subject of an action under section 271(e)(2), the patentee shall be presumed to have disclaimed the patent term for each of the listed patents after the date on which the term of the first patent expires, subject to the exceptions provided for in subsection (2). (2)Demonstration of distinct inventionsIf a patentee demonstrates by a preponderance of the evidence that certain patents described in paragraph (1) cover patentably distinct inventions from the invention claimed in the first such patent to expire, no part of the term of any such patent shall be presumed to have been disclaimed, and all patent term extensions granted by the United States Patent and Trademark Office shall be respected, unless and to the extent the patentee expressly disclaims, in writing, the patent term for each such patent..
(b)USPTO review
(1)DefinitionsIn this subsection— (A)the term Office means the United States Patent and Trademark Office; and
(B)the term Director means the Under Secretary of Commerce for Intellectual Property and Director of the Office. (2)ReviewThe Director shall conduct a comprehensive review of the patent examination procedures of the Office to determine whether the Office—
(A)is using best examination practices, guidance, and procedures to avoid the issuance of patents relating to the same drug, or biological product, that are not patentably distinct from one another, and not subject to an appropriate disclaimer of patent term; and (B)should develop and implement new practices, guidance, or procedures to—
(i)improve examination of patent applications relating to the same drug or biological product; and (ii)reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.
(3)ReportNot later than 1 year after the date of enactment of this Act, the Director shall submit to the Committee on the Judiciary of the House of Representatives a report that contains— (A)the findings from the review conducted under paragraph (2); and
(B)any recommendations of the Director with respect to the review conducted under paragraph (2).


================================================================================

Raw Text:
119 HR 890 IH: Stopping Pharma’s Ripoffs and Drug Savings For All Act
U.S. House of Representatives
2025-01-31
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



I119th CONGRESS1st SessionH. R. 890IN THE HOUSE OF REPRESENTATIVESJanuary 31, 2025Mr. Ryan introduced the following bill; which was referred to the Committee on the JudiciaryA BILLTo amend title 35, United States Code, to prevent double patenting, and for other purposes. 
1.Short titleThis Act may be cited as the Stopping Pharma’s Ripoffs and Drug Savings For All Act.  2.Prevention of double patenting (a)In generalSection 253 of title 35, United States Code, is amended by adding at the end the following:

(c)Disclaimers of drug patent term
(1)In generalExcept as provided in paragraph (2), in a proceeding challenging the validity of patents under section 505(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)) with respect to a drug, under section 351(l) of the Public Health Service Act (42 U.S.C. 262(l)) with respect to a biological product, or a Federal district court proceeding involving patents that are the subject of an action under section 271(e)(2), the patentee shall be presumed to have disclaimed the patent term for each of the listed patents after the date on which the term of the first patent expires, subject to the exceptions provided for in subsection (2). (2)Demonstration of distinct inventionsIf a patentee demonstrates by a preponderance of the evidence that certain patents described in paragraph (1) cover patentably distinct inventions from the invention claimed in the first such patent to expire, no part of the term of any such patent shall be presumed to have been disclaimed, and all patent term extensions granted by the United States Patent and Trademark Office shall be respected, unless and to the extent the patentee expressly disclaims, in writing, the patent term for each such patent..
(b)USPTO review
(1)DefinitionsIn this subsection— (A)the term Office means the United States Patent and Trademark Office; and
(B)the term Director means the Under Secretary of Commerce for Intellectual Property and Director of the Office. (2)ReviewThe Director shall conduct a comprehensive review of the patent examination procedures of the Office to determine whether the Office—
(A)is using best examination practices, guidance, and procedures to avoid the issuance of patents relating to the same drug, or biological product, that are not patentably distinct from one another, and not subject to an appropriate disclaimer of patent term; and (B)should develop and implement new practices, guidance, or procedures to—
(i)improve examination of patent applications relating to the same drug or biological product; and (ii)reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.
(3)ReportNot later than 1 year after the date of enactment of this Act, the Director shall submit to the Committee on the Judiciary of the House of Representatives a report that contains— (A)the findings from the review conducted under paragraph (2); and
(B)any recommendations of the Director with respect to the review conducted under paragraph (2).